Skip to content
Stage · Medium2 outlets · 2 articlesTech

Opentrons raises $40M Series E; says 11,000 robots run in 80+ countries

Opentrons raises $40M Series E; says 11,000 robots run in 80+ countries — Newsmesis editorial illustration
— Newsmesis illustration

What happened

Opentrons Labworks Inc., which makes benchtop pipetting robots, raised $40 million in a Series E round led by healthcare investor Avego with BroadOak Capital Partners, per SiliconANGLE. The company says it has deployed more than 11,000 robots in over 80 countries, including at 90% of the top 20 global pharmaceutical companies. It plans to use the money to scale its robotics, software and data infrastructure. Every figure on deployments and customer reach comes from the company, with no independent check reported.

What we know

SiliconANGLEsiliconangle.comBloomberg (Technology)bloomberg.com
  • Opentrons raised $40 million in a Series E led by Avego, with BroadOak Capital Partners also participating, per SiliconANGLE.
  • The company says it has deployed over 11,000 robots in more than 80 countries, per SiliconANGLE citing Opentrons.
  • Opentrons says 90% of the top 20 global pharmaceutical companies use its robots, per SiliconANGLE citing the company.
  • Its products are the Flex, an enclosed benchtop robot with an optional gripper for moving plates, and the smaller, cheaper OT-2, per SiliconANGLE.
  • Opentrons was founded in 2014 and also sells AI software for sample preparation and repetitive experimental work, per SiliconANGLE.

What we don't know yet

  • The valuation of the round and the total capital raised to date were not disclosed in the source.
  • The deployment count and pharma-customer share are company claims; how 'deployed' and 'top 20' are defined is not stated.
  • Whether the company's AI software runs experiments autonomously at customer sites, or only assists human-designed workflows, is not shown by the source.
  • Revenue, profitability and the split of the 11,000 robots between Flex and OT-2 are unreported.

Why it matters

Lab automation vendors such as Opentrons are positioning physical pipetting hardware as the bottleneck for AI-driven science. For pharma and biotech labs choosing automation, the round shows investor backing for a low-cost benchtop approach rather than large custom robotic systems.

Claims

Related coverage

Town: $108M Series B at a $1B valuation, four months after public launch

Tech ·

Nominal's valuation went from $1B to $3B in eight months on a $240M Series C

Tech ·

Anthropic's Q3 revenue hit $17B, but quarterly growth slowed from 144% to 47%

Tech ·

Why you can trust this story

63%

Source map · 2 outlets / 2 articles

How this credibility score is calculated

  • Source reliability
  • Corroboration
  • Primary source
  • Claims checked against the source
  • No contradiction
  • Settled
  • Claim attribution
  • AI disclosure

Checked claims were verified against the cited source text. Weights are fixed and explainable.

Human accountability

  • 2 independent origins / 2 sources
  • Drafted by an automated system; a human editor approves every story before it is published.

Verification ledger · 4

  • Claim: Opentrons Labworks raised $40 million in a Series E round.
    Status: ConfirmedVerification trailVerifiedChecked by verification engine

    At least one checkable detail was matched against the full text of the cited source.

  • Claim: Avego led the Series E round, with BroadOak Capital Partners also participating.
    Status: ConfirmedVerification trailVerifiedChecked by verification engine

    At least one checkable detail was matched against the full text of the cited source.

  • Claim: Opentrons says it has deployed more than 11,000 robots in over 80 countries.
    Status: UnconfirmedVerification trailUnverifiedChecked by verification engine

    No automated check against the source text is available.

  • Claim: Opentrons says 90% of the top 20 global pharmaceutical companies use its robots.
    Status: UnconfirmedVerification trailUnverifiedChecked by verification engine

    No automated check against the source text is available.

Update log · 0

    AI accelerates. High-risk topics wait for a human editor.